Options
NPC1 as a Modulator of Disease Severity and Viral Entry of SARSCoV- 2
Journal
Current Molecular Medicine
ISSN
1566-5240
Date Issued
2021
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Abstract
<jats:sec>
<jats:title />
<jats:p>The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1,
MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic
variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts
the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its
pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline
Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be
explored.</jats:p>
</jats:sec>
<jats:title />
<jats:p>The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1,
MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic
variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts
the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its
pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline
Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be
explored.</jats:p>
</jats:sec>
Project(s)